Celdara Medical, LLC

Celdara Medical Announces Preclinical Study Demonstrating Improved Kidney Function in Transplantation with Novel Polymer Therapy

LogoCeldara Medical announces the publication of new translational research in the American Journal of Transplantation indicating that a novel polymer therapeutic candidate, APP-103TM, is able to preserve kidney function in preclinical models of kidney ischemia reperfusion injury, including transplantation. The results of the study, led by experts at Brigham and Women's Hospital and Beth Israel Deaconess Medical Center, provides a potential opportunity for expanded criteria kidney donation and much-needed hope for the roughly 750,000 Americans suffering from End-Stage Renal Disease (ESRD) who are awaiting a life-saving transplant.

Celdara Medical Launches New Website for Biomedical Entrepreneurs

LogoCeldara Medical, LLC today announced the launch of an online resource database for biomedical entrepreneurs: bioentrepreneurresources.com. This database was developed by the DRIVEN Accelerator Hub, an NIH-funded consortium led by Celdara Medical including 10 of the leading research institutions in the Northeast region (NH, VT, ME, DE, and RI). The database is open to biomedical entrepreneurs globally and contains resources from across the country. New resources are added by user submission and curated by DRIVEN.

Celdara Medical Receives $2.3M Grant to Advance a Novel Treatment for Acute Kidney Injury

LogoCeldara Medical, LLC today announced that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has awarded a three-year Small Business Innovation Research (SBIR) fast track award to fund the company's advancement of APP-103 for the treatment of acute kidney injury (AKI). This project builds on the inventions of co-collaborator Dr. Peter Kang at the Beth Israel Deaconess Medical Center in Boston.